Results 121 to 130 of about 10,242 (284)

Immunogenicity of Botulinum Toxin Type A in Different Clinical and Cosmetic Treatment, a Literature Review

Life
Background: Botulinum toxin type A is widely utilized for both therapeutic and aesthetic purposes, yet concerns regarding its immunogenicity have raised issues related to treatment failure and adverse reactions.
Kar Wai Alvin Lee, Lisa Kwin Wah Chan, Angela Wai Kay Lee, Cheuk Hung Lee, Jovian Wan, Kyu-Ho Yi   +5 more
doaj   +1 more source

Bacterial Protein Toxins as Anticancer Agents: Clinical Potential of Pseudomonas and Anthrax Toxins

Protein toxins are biologically active polypeptides produced by a variety of organisms, including bacteria, plants, fungi, and animals. These molecules exert potent and specific toxic effects on target cells and are primarily associated with ...
Radhika Gupta, Vishal Sharma, Namita Nayyar, Yogendra Singh, Renu Baweja, Richa Misra, Ritvik Baweja   +6 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Oral Health Care Services, Barriers and Enablers to Maintaining Good Oral Health in Motor Neurone Disease: A Scoping Review

Community Dentistry and Oral Epidemiology, EarlyView.
ABSTRACT Objectives The objective of this scoping review was to map existing literature on oral health and related care in individuals with Motor Neurone Disease (MND). Specifically, the review aimed to identify barriers and facilitators to maintaining oral hygiene, summarise available clinical guidelines and patient‐facing resources, and examine how ...
Mariam A. Khokhar, Lucy A. O'Malley, Anne‐Marie Glenny, Xiaohui Chen   +3 more
wiley   +1 more source

Central effects of botulinum toxin type A: Evidence and supposition

, 2004
No convincing evidence exists that botulinum toxin type A (BT-A) injected intramuscularly at therapeutic doses in humans acts directly on central nervous system (CNS) structures.
Giovanni Abbruzzese, CURRA', antonio, Carlo Trompetto, TROMPETTO, CARLO, CURRA' A., ABBRUZZESE, GIOVANNI, BERARDELLI, Alfredo, BERARDELLI A.   +7 more
core   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

Impact of Early Versus Late Treatment with Botulinum Toxin A on Goal Attainment in Post-Stroke Spasticity: A Retrospective Cohort Study

Toxins
This study evaluated the effect of time of botulinum toxin A (BoNT-A) treatment on clinical outcomes in adults with post-stroke spasticity (PSS). Individual data were pooled from five studies. Eligible patients received ≥1 BoNT-A injection(s) for PSS and
Atul Patel, Jinming Zhang, Simon Page, Sarah Harding, Mathieu Beneteau, Colin Navickas, Alberto Esquenazi   +6 more
doaj   +1 more source

Polyesterase activity and thermostability of carboxylesterases from Thermoleophilum album YS‐3

The FEBS Journal, EarlyView.
Three novel α/β‐hydrolases from thermophilic bacterium Thermoleophilum album display carboxylesterase and polyesterase activity. These enzymes hydrolyse PET, PLA and PCL both at high and moderate temperatures. TA21 shows superior activity, efficiently converting MHET to terephthalic acid. Structural features underlying substrate binding highlight their
Tatyana N. Chernikova, Anna N. Khusnutdinova, Hairong Ma, Manuel Ferrer, Olga V. Golyshina, Alexander F. Yakunin, Peter N. Golyshin   +6 more
wiley   +1 more source

[Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].

Arquivos de neuro-psiquiatria, 2004
Botulinum toxin (BTX) injection is the first choice treatment for focal dystonias. However 10% or more of patients who receive repetitive injections of BTX type A (BTX-A) lose response (secondary non-responders). One of the strategies to manage such patients is to treat them with another serotype.
openaire   +2 more sources

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source